THORAX胸腔
THORAX(英文缩写 THORAX),ISSN 0040-6376,eISSN 1468-3296,中文译名:胸腔 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 9.203 | Q1 |
| 2022 | 10.000 | Q1 |
| 2023 | 9.000 | Q1 |
| 2024 | 7.700 | Q1 |
| 2025 | 9.100 | Q1 |
THORAX 最新收录文献
-
2. Traumatic chylohemothorax revealed by sequential dual pleural fluid layering.
PMID:日期:2026-09-24该文献暂无摘要。
-
3. {"_":"PM, O and survival gains from China's clean air actions among patients with lung cancer: a 20-year registry-based cohort study in Beijing.","sub":["2.5","3"]}
PMID:日期:2026-09-23In recent years, China has experienced declining fine particulate matter (PM) levels but rising ozone (O) levels. We aimed to examine the independent and joint associations of long-term exposure to PM and O with all-cause mortality among patients with lung cancer and to estimate potential survival gains. We included 172 845 lung cancer patients diagnosed in 2003-2022 from the Beijing Cancer Registry. Three-year average pre-diagnosis PM and O were assigned using the ChinaHighAirPollutants dataset. Cox proportional hazards models were used to estimate associations of PM and O with mortality. Joint exposure-response patterns were examined using a two-dimensional tensor-product spline and quantified by the multiplicative interaction index. Model-estimated avoided deaths and extended expected lifespan (EEL) were calculated using counterfactual simulations based on 2013 exposure levels. Both PM and O were associated with increased mortality among patients with lung cancer, with HRs of 1.111 for PM (95% CI 1.083 to 1.140) and 1.117 for O (95% CI 1.070 to 1.166) per 10 μg/m increase. A significant multiplicative interaction was observed between PM and O, with statistically significant positive interactions mainly occurring at higher O concentrations (>105 µg/m). During 2016-2022, reductions in pre-diagnosis PM exposure were associated with 13 229 model-estimated avoided deaths and a 7.8-month increase in 5-year EEL. However, O and the PM-O interaction offset approximately 40% of these benefits. PM reduction was associated with substantial survival gains among lung cancer patients, but rising O and pollutant interactions partly offset these benefits, supporting coordinated multipollutant control.
-
4. Effects of obstructive sleep apnoea treatment on cardiovascular and sleep health in bed partners: the sleep partners clinical trial.
PMID:日期:2026-09-22It remains unclear whether obstructive sleep apnoea (OSA) and its treatment influence cardiovascular and sleep health in bed partners. In this placebo-controlled trial, patients with moderate/severe OSA who had bed partners were randomly assigned to receive continuous positive airway pressure (CPAP) or placebo (nasal strips). At baseline and after 3 months, the bed partners underwent clinical evaluation, endothelial function (flow-mediated dilation, FMD), 24-hour ambulatory blood pressure (BP) monitoring, sleep questionnaires and 1-week wrist actigraphy. A total of 63 couples were recruited (34 patients randomised to CPAP and 29 to nasal strips). At baseline, bed partners showed impaired FMD and a higher frequency of long sleep latency, fragmented sleep, short sleep duration and poor sleep quality. Mean adherence to CPAP and nasal strips in OSA patients was 5.7±1.7 hours and 93.1%±12.6%, respectively. Compared with placebo, bed partners of patients assigned to CPAP did not change FMD (Δ: -0.94% (6.03%; 2.24%) vs Δ: -3.27% (-6.50%; 1.76%), p=0.67). However, significant differences were observed for 24-hour systolic BP (CPAP: -0.85±5.22 mm Hg; placebo: +3.14±8.00 mm Hg; p=0.03), daytime systolic BP (CPAP: -1.2±5.5 mm Hg; placebo: +3.8±8.8 mm Hg; p=0.01) and night-time heart rate (CPAP: -3±6 bpm; placebo: +2±7 bpm; p=0.01). They improved sleep quality (p=0.02), decreased daytime sleepiness (p=0.01), time awake after sleep onset (CPAP: -4.71±20.32 min; placebo: +7.36±17.51 min; p=0.002) and number of awakenings (CPAP: -0.97±9.42; placebo: +2.83±9.14; p=0.02). In a stratified analysis by CPAP adherence, endothelial function in bed partners was preserved with optimal use (≥6 hours/night), but worsened with lower adherence (p=0.03). OSA treatment did not improve endothelial function in bed partners but prevented BP increases, alongside improvements in sleep quality, daytime sleepiness and sleep fragmentation. NCT03011294.
-
5. Inequalities in chronic respiratory disease: working towards policy change?
PMID:日期:2026-09-22该文献暂无摘要。
-
6. Systematic misclassification of lung function in Indian adolescents using GLI-2012 reference equations: evidence from the multicity APEAL cohort.
PMID:日期:2026-09-22Accurate spirometric interpretation depends on appropriate reference equations. The Global Lung Function Initiative (GLI-2012) equations are widely used internationally, but South Asian populations were sparsely represented in their derivation and their applicability in Indian adolescents remains uncertain. We performed a cross-sectional analysis of baseline data from the multicity Air Pollution Exposure on Adolescents' Lungs cohort. Healthy, non-smoking school-going adolescents aged 11-14 years from Delhi, Mumbai, Bengaluru and Mysuru underwent spirometry using standardised American Thoracic Society/European Respiratory Society procedures. GLI-2012 z-scores for forced expiratory volume in 1 s (FEV), forced vital capacity (FVC) and FEV/FVC were calculated using the Asian reference category. Fit was assessed using mean z-scores and the proportion below the lower limit of normal (LLN; z<-1.645). Among 4175 adolescents (2148 males), mean z-scores were -2.44 (SD 1.27) for FEV, -1.34 (0.93) for FVC and -0.78 (1.11) for FEV/FVC, all well outside the accepted ±0.5 range for adequate fit. Overall, 74.6% were below the LLN for FEV, 36.8% for FVC and 19.3% for FEV/FVC, compared with the expected 5% in a well-calibrated healthy population. The leftward shift in z-score distributions was consistent across sex, city, age, height and body mass index strata. GLI-2012 equations, as currently applied in the absence of South Asian-specific references, demonstrated substantial calibration mismatch relative to this cohort of Indian adolescents and risk major overclassification of low lung function. Population-specific validation and recalibration are needed before routine clinical or epidemiological use in this population.
-
7. Associations between accelerated lung function decline and cardiovascular outcomes: a systematic review.
PMID:日期:2026-09-22Emerging evidence suggests that lung function decline may be linked to cardiovascular disease (CVD), but this has not been synthesised to date. This review aims to synthesise the current evidence on accelerated lung function decline and cardiovascular outcomes. We systematically searched MEDLINE, Embase and PubMed from inception to May 2026 for studies evaluating longitudinal changes in lung function in adults in relation to CVD. Study quality was assessed using the Risk Of Bias In Non-randomised Studies of Exposure tool, and findings were synthesised narratively. Of 6772 studies identified from the search, 15 publications met the inclusion criteria: 12 general population cohorts, 2 occupational cohorts and 1 chronic obstructive pulmonary disease (COPD) cohort. In the general/occupational population, accelerated lung function decline was consistently associated with increased cardiovascular risk, with a uniformly positive directional trend and HRs ranging from 1.07 to 1.36 for forced expiratory volume in 1 s (FEV₁) and 1.06 to 1.33 for forced vital capacity. Similar trends were observed for CVD-related biomarkers, risk factors and subclinical cardiovascular phenotypes (eg, HRs 1.04-1.66 for accelerated FEV decline). Potential effect modifiers of these associations such as smoking were reported. However, the association between accelerated lung function decline and CVD mortality in the general population remains inconclusive. In two occupational cohorts, lung function decline was associated with higher CVD mortality risk (HRs 2.05-2.59). In ageing populations, tracking the rate of lung function decline may help identify not only those at risk of COPD but also those at risk of CVD.
-
8. International epidemiology of antimicrobial resistance in people living with chronic lung infection.
PMID:日期:2026-09-21Antimicrobial resistance (AMR) is a global threat for people with chronic lung infection; however, international AMR epidemiology in bronchiectasis and cystic fibrosis (CF) is poorly characterised. In this study, we retrospectively analyse international longitudinal AMR epidemiology in bronchiectasis and CF. Microbiology data were analysed from 110 323 respiratory samples in 19 143 individuals with bronchiectasis or CF across 11 cities, eight countries, three continents between 2011 and 2024. Longitudinal AMR prevalence, multidrug-resistant (MDR) and extensively drug-resistant (XDR) prevalence and multiple antibiotic resistance (MAR) index were analysed by disease and country. Pilot analysis of concurrent/disjoint resistance in antimicrobial pairs and triplets in regional datasets was performed to inform combination or cyclical antimicrobial choice. Geographic AMR differences were noted across pathogens in bronchiectasis and CF with increased resistance in central/southern Europe and increased resistance in Hong Kong. MDR burden was high in emergent pathogens (CF: MDR 32.6%; XDR 12.4%; bronchiectasis: MDR 39.2%; XDR 4.9%) and (CF: MDR 22.7%; XDR 15.6%; bronchiectasis: MDR 13.4%; XDR 1.5%). A longitudinal rise in AMR was seen in bronchiectasis across four centres for antipseudomonal aminoglycosides (p<0.001; OR/year 1.44; 95% CI 1.24 to 1.67), fluoroquinolones (p=0.002; OR/year 1.13; 95% CI 1.05 to 1.23), cephalosporins (p=0.005; OR/year 1.17; 95% CI 1.05 to 1.30), penicillins with beta-lactamase inhibitor (p=0.02; OR/year 1.18; 95% CI 1.03 to 1.35) and carbapenems (p=0.048; OR/year 1.11; 95% CI 1.00 to 1.23). Rising longitudinal AMR was seen for cephalosporins (p=0.01; OR/year 1.32; 95% CI 1.06 to 1.65) and carbapenems (p=0.04; OR/year 1.64; 95% CI 1.03 to 2.62). A significant increase in AMR, as measured by the MAR index, was observed in individuals with residual culture-positive CF receiving triple cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy (p<0.001). Strong concurrent resistance was noted in bronchiectasis across regions with geographic variation in disjoint antimicrobial pair resistance. We show a significant increasing international AMR burden in bronchiectasis and CF, with geographic variation and persistence post-CFTR modulator therapy.
-
9. Generational changes in lung function in adults from several world regions: results from the Burden of Obstructive Lung Disease study.
9. 全球多个地区成年人肺功能的代际变化：阻塞性肺疾病负担研究的结果PMID:日期:2026-09-18This study estimated birth cohort effects on lung function using BOLD (Burden of Obstructive Lung Disease) data from 28 569 adults born between 1902 and 1976 across 41 sites in 34 countries. Forced vital capacity (FVC), forced expiratory volume in 1 s (FEV) and the FEV/FVC increased across successive birth cohorts in both high-income countries (HICs) and low- and middle-income countries (LMICs), with mean values rising steadily with later birth year. In fully adjusted models, FVC increased by 21.4 mL, FEV by 24.6 mL and FEV/FVC by 0.25% per birth year. These positive associations were consistent across sex, smoking status and country-income subgroups (HICs and LMICs).
-
10. Knowing when to stop: the challenge of macrolide discontinuation in chronic airways disease.
PMID:日期:2026-09-18该文献暂无摘要。